Media coverage about Bellicum Pharmaceuticals (NASDAQ:BLCM) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.3878322204692 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several brokerages have commented on BLCM. Jefferies Group restated a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th. Raymond James Financial set a $18.00 price objective on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Finally, BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $26.20.
Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $10.12 on Monday. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $20.19. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08.
In related news, CFO Alan A. Musso sold 6,206 shares of the company’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 18.77% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.